keyword
MENU ▼
Read by QxMD icon Read
search

Chemoembolization with microspheres in liver tumors

keyword
https://www.readbyqxmd.com/read/28392205/radiofrequency-vs-microwave-ablation-after-neoadjuvant-transarterial-bland-and-drug-eluting-microsphere-chembolization-for-the-treatment-of-hepatocellular-carcinoma
#1
Lindsay M Thornton, Roniel Cabrera, Melissa Kapp, Michael Lazarowicz, Jeffrey D Vogel, Beau B Toskich
AIM: To retrospectively compare the initial response, local recurrence, and complication rates of radiofrequency ablation (RFA) vs microwave ablation (MWA) when combined with neoadjuvant bland transarterial embolization (TAE) or drug-eluting microsphere chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). METHODS: A total of 35 subjects with Barcelona Clinic Liver Cancer (BCLC) very early and early-stage HCC (range: 1.2-4.1cm) underwent TAE (23) or TACE (12) with RFA (15) or microwave ablation (MWA) (20) from January 2009 to June 2015 as either definitive therapy or a bridge to transplant...
February 20, 2017: Current Problems in Diagnostic Radiology
https://www.readbyqxmd.com/read/28185998/study-on-the-effect-of-chemoembolization-combined-with-microwave-ablation-for-the-treatment-of-hepatocellular-carcinoma-in-rats
#2
Thomas Josef Vogl, Jun Qian, Andreas Tran, Elsie Oppermann, Nagy N Naguib, Huedayi Korkusuz, Nour Eldin A Nour Eldin, Wolf Otto Bechstein
PURPOSE: We aimed to evaluate the combining effects of transarterial chemoembolization (TACE) and open local thermal microwave ablation in a hepatocellular carcinoma animal model. METHODS: Tumor cubes were implanted into the liver of 30 male inbred ACI rats. Groups of 10 animals were treated at 13 days (TACE or microwave ablation) and 16 days (microwave ablation) postimplantation with combined therapy of TACE (0.1 mg mitomycin C; 0.1 mg iodized oil; 5.0 mg degradable starch microspheres) and microwave ablation (2450 Mhz; 45 s; 35 W) (study group A), TACE alone (control group B), or microwave ablation alone (control group C)...
March 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/28166821/deb-tace-for-intermediate-and-advanced-hcc-initial-experience-in-a-brazilian-cancer-center
#3
Jose Hugo Mendes Luz, Paula M Luz, Henrique S Martin, Hugo R Gouveia, Raphal Braz Levigard, Felipe Diniz Nogueira, Bernardo Caetano Rodrigues, Tiago Nepomuceno de Miranda, Marcelo Henrique Mamede
BACKGROUND: According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arterial administration. This type of transarterial chemoembolization approach appears to provide at least equivalent effectiveness with less toxicity. METHODS: This is a prospective, single-center study, which evaluated 21 patients with intermediate and advanced hepatocellular carcinoma who underwent transarterial chemoembolization with drug-eluting microspheres...
February 6, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28046479/we-ab-bra-05-pet-guided-delivery-quality-evaluation-of-yttrium-90-microsphere-radioembolizaton-for-hepatocellular-carcinoma-patients-the-optimal-sequence-of-radioembolizaton-and-chemoembolization-treatments
#4
M Lin, B Saboury
PURPOSE: Selective-internal-radiation-therapy (SIRT) and transarterial-chemoembolization (TACE) are commonly used for treatment of liver tumors. The use of TACE, which is macroembolic, prior to SIRT may cause hemodynamic changes in tumor vasculature that impair yttrium-90 (90Y) microsphere delivery to the targeted lesions. This work aims to quantify dosimetric tumor coverage using 90Y positron emission tomography (PET) dosimetry after SIRT alone compared to TACE followed by SIRT. METHODS: A total of 40 consecutive hepatocellular carcinoma (HCC) SIRT patients who had a post-SIRT 90Y PET/CT scan were evaluated...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28036272/chemoembolization-of-liver-cancer-with-drug-loading-microsphere-50-100%C3%AE-m
#5
Jun-Hui Sun, Guan-Hui Zhou, Yue-Lin Zhang, Chun-Hui Nie, Tan-Yang Zhou, Jing Ai, Tong-Yin Zhu, Wei-Lin Wang, Shu-Sen Zheng
Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for unresectable hepatocellular carcinoma (HCC). The efficacy of conventional TACE (cTACE) in liver metastases is not satisfactory, which might be due to the fact of embolic material used. Recently, as a new type of drug-loading microsphere, HepaSphere has been introduced in China. In this study, there were total 30 patients (18 males and 12 females) with liver cancer underwent embolization with Hepasphere microsphere. And a total of 44 TACE procedures were performed using 50-100μm HepaSphere...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28035432/chemoembolization-of-neuroendocrine-liver-metastases-using-streptozocin-and-tris-acryl-microspheres-embozar-embosphere%C3%A2-%C3%A2-zanosar-study
#6
Jean-Pierre Pelage, Audrey Fohlen, Emmanuel Mitry, Christine Lagrange, Alain Beauchet, Philippe Rougier
PURPOSE: The purpose of this prospective observational study was to evaluate the efficacy and tolerability of transarterial chemoembolization (TACE) for neuroendocrine liver metastases using a combination of streptozocin, Lipiodol, and tris-acryl microspheres. PATIENTS AND METHODS: A total of 16 men and 9 women aged 59.6 ± 11.3 years, all with predominant liver disease, underwent 54 courses of TACE using an emulsion of 1.5 g of streptozocin and 10 ml of Lipiodol...
March 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27999917/radiofrequency-ablation-combined-with-hepatic-arterial-chemoembolization-using-degradable-starch-microsphere-mixed-with-mitomycin-c-for-the-treatment-of-liver-metastasis-from-colorectal-cancer-a-prospective-multicenter-study
#7
Koichiro Yamakado, Yasutaka Inaba, Yozo Sato, Taku Yasumoto, Sadao Hayashi, Takashi Yamanaka, Koji Nobata, Haruyuki Takaki, Atsuhiro Nakatsuka
PURPOSE: This phase II prospective study investigates possible benefits of radiofrequency ablation (RFA) combined with hepatic arterial chemoembolization using degradable starch microsphere (DSM) mixed with mitomycin C (MMC) in non-surgical candidates with colorectal liver metastases. MATERIALS AND METHODS: This study, approved by the respective institutional review board, included non-surgical candidates with 3 or fewer liver tumors of 3 cm or smaller, or a single lesion 5 cm or smaller...
December 20, 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27904450/survival-of-patients-with-intermediate-stage-hepatocellular-carcinoma-treated-with-superselective-transarterial-chemoembolization-using-doxorubicin-loaded-dc-bead-under-cone-beam-computed-tomography-control
#8
Peter Popovic, Borut Stabuc, Rado Jansa, Manca Garbajs
BACKGROUND: The purpose of this retrospective study was to evaluate treatment response, adverse events and survival rates of patients with intermediate stage HCC treated with superselective doxorubicin-loaded DC Bead transarterial chemoembolization (DEBDOX) under cone beam computed tomography (CBCT) control. PATIENTS AND METHODS: Between October 2010 and June 2012, 35 consecutive patients with intermediate stage HCC (32 male, 3 female; average age, 67.5 ± 7.8 years; 22 patients Child-Pugh class A, 8 class B, 5 without cirrhosis) were treated with DEBDOX TACE...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27872985/pharmacokinetics-and-histopathological-findings-of-chemoembolization-using-cisplatin-powder-mixed-with-degradable-starch-microspheres-in-a-rabbit-liver-tumor-model
#9
Takeshi Sato, Toshihiro Tanaka, Hideyuki Nishiofuku, Yasushi Fukuoka, Hiroshi Sakaguchi, Tetsuya Masada, Shota Tatsumoto, Nagaaki Marugami, Masato Takano, Ichiro Yamato, Masayuki Sho, Chiho Ohbayashi, Toshiko Hirai, Kimihiko Kichikawa
PURPOSE: The purpose of this study is to evaluate the pharmacokinetics and histopathological findings of transarterial chemoembolization (TACE) using cisplatin powder mixed with degradable starch microspheres (DSM) (Cis/DSM-TACE) compared with cisplatin arterial infusion (Cis-AI). MATERIALS AND METHODS: Eighteen rabbits with VX2 liver tumors were divided into two groups: Cis/DSM-TACE (n = 9) and Cis-AI (n = 9) groups. In the Cis/DSM-TACE group, a mixture of cisplatin powder and DSM was injected until stasis of hepatic arterial flow was achieved...
March 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27563661/therapeutic-strategies-in-hcc-radiation-modalities
#10
REVIEW
R Gallicchio, A Nardelli, P Mainenti, A Nappi, D Capacchione, V Simeon, C Sirignano, F Abbruzzi, F Barbato, M Landriscina, G Storto
Patients with hepatocellular carcinoma (HCC) comply with an advanced disease and are not eligible for radical therapy. In this distressed scenario new treatment options hold great promise; among them transarterial chemoembolization (TACE) and transarterial metabolic radiotherapy (TAMR) have shown efficacy in terms of both tumor shrinking and survival. External radiation therapy (RTx) by using novel three-dimensional conformal radiotherapy has also been used for HCC patients with encouraging results while its role had been limited in the past for the low tolerance of surrounding healthy liver...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27424988/transarterial-chemoembolization-with-degradable-starch-microspheres-dsm-tace-an-alternative-option-for-advanced-hcc-patients-preliminary-results
#11
R Iezzi, M Pompili, M Nestola, M Siciliano, E Annicchiarico, M A Zocco, E Rinninella, A Posa, G E M Antonuccio, A Gasbarrini, L Bonomo
OBJECTIVE: To assess safety, feasibility and effectiveness of transarterial chemoembolization with degradable-starch-microspheres (DSM-TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC) dismissing or ineligible for multikinase-inhibitor chemotherapy administration (Sorafenib) due to unbearable side effects or clinical contraindications. PATIENTS AND METHODS: Six consecutive advanced HCC patients dismissing Sorafenib because of unbearable side effects or worsened clinical conditions were enrolled in our prospective single-center pilot study...
July 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27284478/ki67-score-as-a-potential-predictor-in-the-selection-of-liver-directed-therapies-for-metastatic-neuroendocrine-tumors-a-single-institutional-experience
#12
Smit Singla, Charles M LeVea, Venkata K Pokuri, Kristopher M Attwood, Michael M Wach, Garin M Tomaszewski, Boris Kuvshinoff, Renuka Iyer
BACKGROUND: Neuroendocrine tumors (NETs) metastatic to the liver are treated with transarterial radioembolization (TARE) using yttrium-90 (Y-90) microspheres or transarterial chemoembolization (TACE). However the criteria for patient selection are not well defined. We sought to determine if Ki67 score could help select patients for one therapy over the other in the management of hepatic neuroendocrine metastases. METHODS: Single institution analysis of patients treated with Y-90 or TACE between 2001 and 2014...
June 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/27275096/transarterial-administration-of-integrin-inhibitor-loaded-nanoparticles-combined-with-transarterial-chemoembolization-for-treating-hepatocellular-carcinoma-in-a-rat-model
#13
Jun Qian, Elsie Oppermann, Andreas Tran, Ulli Imlau, Kun Qian, Thomas Josef Vogl
AIM: To compare the effect of transarterial chemoembolization (TACE) plus GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro, integrin-inhibitor) loaded nanoparticles with TACE alone or TACE + GRGDSP in a rat model of liver tumor. METHODS: Morris hepatoma 3924A tumors were implanted in the livers of 30 ACI rats. The ACI rats were divided randomly into three groups (10 animals each). Tumor volume before treatment (V1) was examined by magnetic resonance imaging (MRI), and then, after laparotomy and placement of a PE-10 catheter into the hepatic artery, the following interventional protocols were performed: TACE (mitomycin C + lipiodol + degradable starch microspheres) + GRGDSP loaded nanoparticles for group A; TACE + GRGDSP for group B (control group 1); TACE alone for group C (control group 2)...
June 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27247711/current-status-of-transarterial-radioembolization
#14
REVIEW
Andreas H Mahnken
Unresectable primary and secondary liver malignancies present a major problem in the treatment of solid tumors. Transarterial radioembolization (TARE) is an increasingly used technique for treating various types of malignant liver tumors. This approach is appealing, as the mechanism of action is independent from other loco-regional treatments and potentially complementary to systemic therapies. There are two commercially available products in use for TARE: (90)Y-resin and (90)Y-glass microspheres. Currently available data indicates TARE so be safe and effective in hepatocellular carcinoma (HCC) and metastatic liver disease...
May 28, 2016: World Journal of Radiology
https://www.readbyqxmd.com/read/27039186/transarterial-radioembolization-with-yttrium-90-for-the-treatment-of-hepatocellular-carcinoma
#15
REVIEW
Joseph Ralph Kallini, Ahmed Gabr, Riad Salem, Robert J Lewandowski
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. METHODS: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC...
May 2016: Advances in Therapy
https://www.readbyqxmd.com/read/26933423/case-report-of-cirrhosis-following-yttrium-90-radioembolization-for-pancreatic-neuroendocrine-liver-metastases
#16
Jonathan M Loree, Tadaaki Hiruki, Hagen F Kennecke
BACKGROUND: Management options for pancreatic neuroendocrine tumors (pNETs) metastatic to the liver include surgical, ablative, cytotoxic, and radioisotope approaches. One potential local treatment option includes selective internal radiotherapy utilizing yttrium-90 ((90)Y) microspheres. (90)Y has also been used in the treatment of hepatocellular carcinoma and tumors metastatic to the liver. It appears to be well tolerated; however, there is no randomized controlled trial reporting long-term toxicities...
January 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/26834067/randomized-trial-of-hepatic-artery-embolization-for-hepatocellular-carcinoma-using-doxorubicin-eluting-microspheres-compared-with-embolization-with-microspheres-alone
#17
Karen T Brown, Richard K Do, Mithat Gonen, Anne M Covey, George I Getrajdman, Constantinos T Sofocleous, William R Jarnagin, Michael I D'Angelica, Peter J Allen, Joseph P Erinjeri, Lynn A Brody, Gerald P O'Neill, Kristian N Johnson, Alessandra R Garcia, Christopher Beattie, Binsheng Zhao, Stephen B Solomon, Lawrence H Schwartz, Ronald DeMatteo, Ghassan K Abou-Alfa
PURPOSE: Transarterial chemoembolization is accepted therapy for hepatocellular carcinoma (HCC). No randomized trial has demonstrated superiority of chemoembolization compared with embolization, and the role of chemotherapy remains unclear. This randomized trial compares the outcome of embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres. MATERIALS AND METHODS: At a single tertiary referral center, patients with HCC were randomly assigned to embolization with microspheres alone (Bead Block [BB]) or loaded with doxorubicin 150 mg (LC Bead [LCB])...
June 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26805063/-pre-operative-treatment-with-transcatheter-arterial-chemoembolization-tace-and-hepatic-arterial-infusion-hai-for-liver-metastasis-from-gastric-cancer-a-case-report
#18
Takahiko Tanigawa, Yasunori Hasuike, Yousuke Akiyama, Ichiro Higuchi, Akira Ishikawa, Atsuya Okada, Makoto Miyamoto
The patient was an 83-year-old man who underwent distal gastrectomy for gastric cancer (T3, N1, M0, P0, M0, stage ⅡB) at a different hospital from ours. A metastatic lesion was detected in the liver 5 months after gastrectomy. Although chemotherapy with S-1 or bi-weekly CPT-11 was administered for 6 months, the liver tumor increased in size. The patient was referred to our hospital for treatment of the liver metastasis. Abdominal-computed tomography (CT) and magnetic resonance imaging (MRI) revealed a solitary metastatic liver tumor (9 cm in diameter: S7/S6/S8) with a hypervascular tumor stain...
November 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26140089/downstaging-disease-in-patients-with-hepatocellular-carcinoma-outside-up-to-seven-criteria-strategies-using-degradable-starch-microspheres-transcatheter-arterial-chemo-embolization
#19
Antonio Orlacchio, Fabrizio Chegai, Stefano Merolla, Simona Francioso, Costantino Del Giudice, Mario Angelico, Giuseppe Tisone, Giovanni Simonetti
AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular carcinoma (HCC), treated with degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE), to reach new-Milan-criteria (nMC) for transplantation. METHODS: This study was approved by the Ethics Committee of our institution. From September 2013 to March 2014 eight patients (5 men and 3 women) with liver cirrhosis and multinodular HCC, that did not meet nMC at baseline, were enrolled in this study...
June 28, 2015: World Journal of Hepatology
https://www.readbyqxmd.com/read/26085914/effective-treatment-strategies-other-than-sorafenib-for-the-patients-with-advanced-hepatocellular-carcinoma-invading-portal-vein
#20
REVIEW
Su Jong Yu, Yoon Jun Kim
Patients with hepatocellular carcinoma (HCC) accompanying portal vein tumor thrombosis (PVTT) have relatively few therapeutic options and an extremely poor prognosis. These patients are classified into barcelona clinic liver cancer stage C and sorafenib is suggested as the standard therapy of care. However, overall survival (OS) gain from sorafenib is unsatisfactory and better treatment modalities are urgently required. Therefore, we critically appraised recent data for the various treatment strategies for patients with HCC accompanying PVTT...
June 18, 2015: World Journal of Hepatology
keyword
keyword
72037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"